anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A preparation method of a composite nano-particle aluminum adjuvant relates to the technical field of vaccine adjuvants, in particular to a preparation method of a nano-composite vaccine adjuvant. The preparation method aims to solve the problems that the existing aluminum salt adjuvant lacks the capability of inducing Th1 type immunoreaction and cannot induce mucosal immunoreaction. The method comprises the following steps: 1. preparing a soluble aluminum salt solution. 2. Preparing the N-2-hydroxypropyl trimethyl ammonium chloride chitosan with controllable substitution degree. 3. Dissolving the N-2-HACC prepared in the step two in a sodium acetate buffer solution, and stirring to prepare an N-2-HACC solution; 4. and adding the anionic polymer solution into the N-2-HACC solution, and uniformly stirring to obtain a mixed solution. 5. Preparing the N-2-HACC-Al composite nano particle aluminum adjuvant. The method can improve the yield on the premise of controlling the particle size, and greatly increase the yield. Positively charged and stable nanoparticles show good delivery and immune enhancement. The invention is used for preparing the aluminum adjuvant for the vaccine.
The present invention has as its object the provision of an aerosol product for forming a cooling gel composition for the human body. The aerosol product can easily and stably form a cooling gel composition for the human body which has high storage stability and which provides comfort during use and a sufficient cooling effect. 
     The aerosol product for forming a cooling gel composition for the human body of the present invention has a double-structure container including a propellant filling space and two liquid concentrate filling spaces and having a discharging mechanism for simultaneously discharging the contents filled in these two liquid concentrate filling spaces. The propellant filling space is filled with a propellant composed of a compressed gas. A first liquid concentrate filling space is filled with a first liquid concentrate composition containing a hydrated endothermic substance dispersed in a liquid medium. A second liquid concentrate filling space contains a second liquid concentrate composition containing water. The first liquid concentrate composition and the second liquid concentrate composition, which have a viscosity of 1,000 to 125,000 mPa·s at a temperature of 20° C., are mixed to form a cooling gel composition for the human body.
Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
In this group, the mother breastfed her baby for 20 minutes before vaccination. Breastfeeding was terminated before vaccination. FLACC pain scale, SPO2, and pulse oximetry were evaluated and recorded 5 min before and 2 min after vaccination, immediately before vaccination, immediately after vaccination (pain during the procedure), and 2 and 5 min after the procedure.
The invention relates to a bone-knitting medicine for detoxication, detumescence, removement of blood stasis and treatment of injuries from falls, belonging to the technical field of pharmacy, in particular to a medicine which can knit bone and take away the pain quickly and has the functions of detoxication, detumescence, removement of blood stasis and defervescence, namely, the hereditary secret formula of Meng bone-knitting--Baligong medicine. The invention comprises the active pharmaceutical ingredients of the following parts by weights: 8 to 12 portions of gardenia, 6 to 10 portions of phellodendron bark, 4 to 8 portions of tree peony bark, 4 to 8 portions of cutch, 2 to 5 portions of borax, 0.3 to 0.8 portions of camphor and 0.4 to 1 portions of mint ice. The preparation method is as follows: first, weigh the gardenia, phellodendron bark, tree peony bark, cutch, borax, camphor and mint ice according to the prescription; then crush the active pharmaceutical ingredients into powder and use honey to mix. The bone-knitting medicine is mainly for treating injuries from falls, fracture, inflammation, malignancy neoplasm, pressing pain, blood stasis, turgescence and gout. The bone-knitting medicine is characterized in fewer medications, low price and obvious effect of pain relief. The bone-knitting medicine has the advantages of reliable curative effect, simple manufacture, no poison and side effect and quick effect of pain relief and detumescence.
The invention provides a traditional Chinese medicine used for treating gastrosis and a preparation method thereof. The traditional Chinese medicine comprises, by weight, 1 part of gizzard lining and 0.2 part of aloe powder. The preparation method includes the following steps: (1) removing impurities of the gizzard lining, soaking with water for 24-36 hours, taking the gizzard lining and cleaning, (2) drying the cleaned gizzard lining, frying slowly until the gizzard lining is plump, taking the gizzard lining out, adding the aloe powder rapidly, evenly mixing, sealing and storing for 24-48 hours, and smashing to obtain the traditional Chinese medicine used for treating the gastrosis. By means of the gizzard lining soaked with the aloe, the traditional Chinese medicine used for treating the gastrosis has large astringent and healing effects on stomach inflammation and ulcer cambiums. Besides, odor of the gizzard lining is removed, so special effects such as inflammation prevention, sterilization and stomach fortifying are enhanced. The medicine further has a function of inhibiting helicobacter pylori, and therefore treatment effects are remarkable. The traditional Chinese medicine is remarkable in treatment effect, safe, and efficient. Cure efficiency is 96.4%.
Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
Chronic pain affects many spheres of the lives of affected individuals and those around them. In Canada, the prevalence of chronic pain is estimated at 15% of adults aged 18 and over. Among seniors, the prevalence of this health problem can reach up to 50% and affect one in two seniors. Chronic pain is one of the leading causes of work disability. In this context, pain reduction remains one of the most effective methods to enable the worker to stay at work. Considering the aging Quebec population, labor needs and the average retirement age which is increasingly postponed, it becomes crucial to take an interest in aging workers and their continued employment.

Transcranial direct current stimulation (tDCS) is a non-invasive neurostimulation method that has shown promise in reducing chronic pain. Recently, several research teams have shown that tDCS has beneficial effects on pain, physical function and social participation in seniors. Despite all these recent advances, very few studies have focused on optimizing tDCS treatment modalities and no studies have focused on the impact of tDCS on return to work or retention. The vast majority of studies using tDCS to reduce pain give one tDCS session per day for 5 consecutive days. This study aims to document the effect of tDCS on pain and work retention in older workers and to compare the traditional tDCS protocol (5 sessions) with an enhanced protocol (11 sessions).
Significant coronary disease (diameter stenosis \>50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
The invention relates to a traditional Chinese medicine composition for treating dysentery and haemorrhoids and a preparation method. The composition is characterized by having the functions of clearing away heat and toxic materials, stopping bleeding and preventing inflammations, stopping dysentery and relieving pains, purging gut and relaxing the bowels, inducing diuresis and reducing edema, dispelling wind and removing obstruction in the meridians and the like. The matrix is prepared from the traditional Chinese medicine compositions according to weight part and an excipient in the pharmaceutical sense: scutellaria baicalensis, amaranthus spinosus, angelica sinensis, verbena, long stephania herb, eclipta alba, divaricate saposhnikovia roots, immature bitter oranges and the like. The traditional Chinese medicine composition provided by the invention can relax the bowels and stop dysentery with two-ways regulation. The traditional Chinese medicine composition has the effect of safe, wide and convenient general treatment on intestinal disease such as dysentery and haemorrhoids. At present, in the 6 cases of patients with haemorrhoids are treated by the composition, the youngest patient is 12 years old, the oldest is 55 years old, and the longest course of disease is 13 years. All the patients are cured. In 22 cases of patients with dysentery, the patients are cured in half a day in the fastest manner, and the patients are cured in the lowest manner in three days. In 7 cases of patients with constipation, defecation is completed by delivering the composition once.
All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
The group will have a neurodevelopmental treatment program (BOBATH treatment approach) and diaphragmatic breathing exercises. Diaphragmatic breathing; To give the patient a supine position, a pillow is placed under his knees and head. The patient is asked to place his right hand on the upper abdomen and his left hand on the upper part of his chest. The patient is told to take a slow and deep breath through the nose until four counts, and to hold the air in for the time it has inhaled, and then the patient shrinks her lips like a whistle and exhales from using her breath for a long time. Exercises are performed two hours after meals, in short, 2-3 minutes in the beginning, in 10 of the patients, on average 30 minutes per day.
Patients receive vorinostat PO QD for 28 days and then receive gallium Ga 68 gozetotide IV and undergo a PET scan on trial. Patients may go on to receive 177Lu-PSMA-617 IV per SOC on day 1 of each cycle. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT and bone scan on trial and during follow-up, as well as a SPECT/CT and FDG PET/CT during screening and on trial. Patients undergo blood sample collection on trial and may also optionally undergo biopsy during screening and on trial.
BACKGROUND: Respiratory diseases pose a grave threat to human life. Therefore, understanding their pathogenesis and therapeutic strategy is important. Ferroptosis is a novel type of iron-dependent programmed cell death, distinct from apoptosis, necroptosis, and autophagy, characterised by iron, reactive oxygen species, and lipid peroxide accumulation, as well as glutathione (GSH) depletion and GSH peroxidase 4 (GPX4) inactivation. A close association between ferroptosis and the onset and progression of respiratory diseases, including chronic obstructive pulmonary disease, acute lung injury, bronchial asthma, pulmonary fibrosis, and lung cancer, has been reported. Recent studies have shown that traditional Chinese medicine (TCM) compounds exhibit unique advantages in the treatment of respiratory diseases owing to their natural properties and potential efficacy. These compounds can effectively regulate ferroptosis by modulating several key signalling pathways such as system Xc- -GSH-GPX4, NCOA4-mediated ferritinophagy, Nrf2-GPX4, and Nrf2/HO-1, thus playing a positive role in improving respiratory diseases.
PURPOSE: This comprehensive review systematically outlines the regulatory role of ferroptosis in the onset and progression of respiratory diseases and provides evidence for treating respiratory diseases by targeting ferroptosis with TCM compounds. These insights aim to offer potential remedies for the clinical prevention and treatment of respiratory diseases.
STUDY DESIGN AND METHODS: We searched scientific databases PubMed, Web of Science, Scopus, and CNKI using keywords such as "ferroptosis","respiratory diseases","chronic obstructive pulmonary disease","bronchial asthma","acute lung injury","pulmonary fibrosis","lung cancer","traditional Chinese medicine","traditional Chinese medicine compound","monomer", and "natural product" to retrieve studies on the therapeutic potential of TCM compounds in ameliorating respiratory diseases by targeting ferroptosis. The retrieved data followed PRISMA criteria (preferred reporting items for systematic review).
RESULTS: TCM compounds possess unique advantages in treating respiratory diseases, stemming from their natural origins and proven clinical effectiveness. TCM compounds can exert therapeutic effects on respiratory diseases by regulating ferroptosis, which mainly involves modulation of pathways such as system Xc- -GSH-GPX4,NCOA4-mediated ferritinophagy, Nrf2-GPX4, and Nrf2/HO-1.
CONCLUSION: TCM compounds have demonstrated promising potential in improving respiratory diseases through the regulation of ferroptosis. The identification of specific TCM-related inducers and inhibitors of ferroptosis holds great significance in developing more effective strategies. However, current research remains confined to animal and cellular studies, emphasizing the imperative for further verifications through high-quality clinical data.
Subjects with clinically confirmed breast cancer and who are treatment naive will provide a stool sample within 30 days of enrollment. No additional stool sample collections will occur.
Disclosed is a method, a device, a system and/or a manufacture of efficient confirmation of a suspect condition for certification and/or re-certification by a clinician. In one embodiment, a method includes extracting a health data of the patient from an electronic medical record (EMR) and applying an assessment ruleset and/or a re-certification evaluation to generate a suspect health condition. An EMR request for health information generated within a native encounter between the patient and the clinician is generated by a computing device of the clinician. The suspect condition data is then integrated in visual association with diagnosed condition(s) within the clinical documentation workflow of an application running on the computing device. A condition certification is received from the computing device and a new record created in the EMR entered and/or a re-certification specified. An updated health data may be assessed in real time and/or automatically detect compliance with documentation requirements.
A preparation is disclosed for producing enhanced blood flow in tissue thus causing beneficial effects such as warming cold tissue of the hands and feet. Specifically, this is a preparation which provides local delivery of the amino acid L-arginine, an important biological precursor to the main substance which is responsible for relaxation of blood vessels permitting enhancement of blood flow. In the preferred embodiments, the L-arginine is provided so that it can be topically applied to the cold tissue. The preparation also contains agents which aids in the transfer of L-arginine into the tissue. In the preferred embodiments this agent overcomes the resistance to transfer caused by the high charge density of L-arginine. In the preferred embodiments this means is high ionic strength created by addition of choline chloride, magnesium chloride and sodium chloride. This preparation, when topically applied to cold tissue, warming begins within about 10 to 45 minutes and is sustained for periods as long as about 2 to 18 hours.
Disclosed herein are wound healing products and methods of making and using the same. The wound healing product comprises a porous scaffold and collagen bound thereon. The scaffold may comprise a a poly(L-lactide-co-8-caprolactone) polymer (PLCL) substrate. In some embodiments, the PLCL substrate comprises a mixture of poly(lactic acid) (PLA) and poly(s-caprolactone) (PLC) and wherein the PLA and PLC are present in a ratio of about 60:40 to about 40:60. In some embodiments, the collagen is collagen I or collagen III. The scaffold may also have a thickness of at least 0.2 mm.
TARKA 2/180 mg tablets are supplied as pink, oval, film-coated tablets containing 2 mg trandolapril in an immediate release form and 180 mg verapamil hydrochloride in a sustained release form. The tablet is debossed with a triangle and 182 on one side and plain on the other side.

TARKA 2/240 mg tablets are supplied as gold, oval, film-coated tablets containing 2 mg trandolapril in an immediate release form and 240 mg verapamil hydrochloride in a sustained release form. The tablet is debossed with a triangle and 242 on one side and plain on the other side.

TARKA 4/240 mg tablets are supplied as reddish-brown, oval, film-coated tablets containing 4 mg trandolapril in an immediate release form and 240 mg verapamil hydrochloride in a sustained release form. The tablet is debossed with a triangle and 244 on one side and plain on the other side.

Dispense in well-closed container with safety closure.
After identifying all patients who were recommended endocrine therapy, data will be linked to the Norwegian Prescription Database (NorPD). Adherence will be estimated based on to which extent the patients actually have effectuated their prescriptions at Norwegian pharmacies. In the 5-year long treatment period, the patients receive a prescription refill of tamoxifen or aromatase inhibitor tablets for a 100 days interval. Medication Possession Ratio (MPR) will be used as proxy for adherence. The estimations will be performed in the following way: For each patient, we will receive the total number of pills and the total length of time from first to latest prescription effectuated. MPR is the number of pills divided by the total number of days in the time from first prescription to discontinuation. Discontinuation will be estimated to date for latest effectuation of the prescription plus 100 days (due to the number of pills prescribed). From these estimations, we will categorize the patients in groups taking MPR and total period of time into consideration. Taking prescript medication equal to or more than 80% is considered as adherent (MPR ≥ 80 %). Likewise, non-adherence is defined as MPR \< 80 %.
PURPOSE: Recurrence and contralateral metachronous inguinal hernia (CMIH) are important postoperative complications in patients with inguinal hernia (IH) who undergo laparoscopic percutaneous extraperitoneal closure (LPEC). This study aimed to evaluate the incidence and causes of recurrence and CMIH after LPEC.
METHODS: Among the included patients, 2484 hernias were included in the analysis of recurrence. CMIH was analyzed in 2094 cases with unilateral IH without a history of contralateral IH.
RESULTS: Overall, 21 hernias (0.85%) recurred and seven patients (0.34%) experienced CMIH. Based on the video inspection, injury and skipping of the peritoneum were suspected as the cause of recurrence in eight cases, while loose ligation was suspected in five cases. The cause of recurrence could not be predicted in the remaining eight patients. Of the seven patients with CMIH, three had a mild depression around the internal inguinal ring at the first surgery. In the remaining four CMIH cases, no noteworthy findings were noted around the internal ring.
CONCLUSIONS: More than half of the recurrences, in which skipping of the peritoneum and loose ligation were suspected, could have been prevented by secure ligation during the first surgery. Extending the indications of prophylactic surgery for shallow depressions may reduce CMIH.
BACKGROUND: No established standard of care exists for relapsed/refractory (RR) follicular lymphoma (FL) after ≥2 prior therapies. We conducted indirect treatment comparisons (ITCs) to compare the efficacy and tolerability of mosunetuzumab with those of available treatments used in this setting.
METHODS: A systematic literature review (SLR) and subsequent feasibility assessments were conducted to identify the most suitable comparator studies in terms of design, available endpoints and populations. Imbalances in patient characteristics between NCT02500407 and studies featuring aggregate or patient-level data availability were accounted for using matching-adjusted indirect comparison (MAIC) and propensity score-based methodologies, respectively.
RESULTS: ZUMA-5, ELARA, DELTA, DYNAMO, UNITY-NHL, AUGMENT and NCT01897571 passed the MAIC feasibility assessment. Patient-level data were available from GADOLIN, CONTRALTO and NCT02257567. MAIC results generally favored mosunetuzumab over tazemetostat in EHZ2wild-type patients for all outcomes and over PI3K inhibitors for complete response (CR), objective response rate (ORR), discontinuations due to adverse events and progression-free survival (PFS) with umbralisib. MAICs favored CART therapies for PFS and, to a lesser extent, ORR and CR. Comparisons with anti-CD20 antibody-based regimens yielded mixed results.
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.
OBJECTIVES: Percutaneous Vocal Fold Lateralization (PVFL) consists of external fixation with non-absorbable percutaneous suture of the vocal fold in a lateral position, under direct glottic visualization. The objective of this study is to determine the effectiveness of PVFL in a university pediatric hospital, as well as to describe the potential risks and complications of the surgery.
METHODS: Retrospective cohort study, with data collected from electronic medical records. The study was approved by the Research Ethics Committee of the institution. Surgeries were performed with the modified Lichentenberg technique and data, and outcomes were analyzed.
RESULTS: Six patients with Bilateral Vocal Fold Paralysis who underwent Percutaneous Vocal Fold Lateralization were evaluated. Three patients were male. The age at diagnosis ranged from 2 to 132 days (mean 10.5 days). The reason for investigating the upper airway was the presence of increased work of breathing and stridor. Five patients had a favorable clinical evolution, with spontaneous ventilation in room air and absence of stridor or ventilatory effort, without the need for tracheostomy. Surgical results in this series corroborate the findings of other similar cohorts, which showed Percutaneous Vocal Fold Lateralization as a safe and effective procedure in avoiding tracheostomy or allowing decannulation in children with Bilateral Vocal Fold Paralysis.
CONCLUSIONS: PVFL seems to be a safe and effective procedure, but it has morbidity, due to immediate, and probably late, non-serious complications. Studies with a larger number of patients, with longer follow-up and using a controlled and randomized clinical design are needed to establish the role of PVFL in the treatment of BVFP in newborns and infants.
LEVELS OF EVIDENCE: Level 4 (step 4).